Cidara Therapeutics

6310 Nancy Ridge Drive Suite 101
San Diego, CA 92121
United States

Tel: (858) 752-6170

About Cidara Therapeutics

Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE). Cidara is also advancing a second Phase 3 trial of once-weekly rezafungin for prophylaxis against invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT) initially in Europe and Canada. In addition to its robust rezafungin clinical program, Cidara is applying its proprietary Cloudbreak® platform to develop antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases. The Cloudbreak platform is designed to discover compounds that both directly kill pathogens and direct a patient’s immune system to attack and eliminate pathogens. Cidara is headquartered in San Diego, California.

184 articles about Cidara Therapeutics

Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress

7/27/2021

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and pre-clinical data, including updated analyses from the Phase 2 STRIVE study and an in vitro evaluation of rezafungin activity against Candida and Aspergillus spp.
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 07, 2021

7/7/2021

Cidara Therapeutics, Inc. announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 172,000 shares of its common stock to eight new employees, pursuant to the Cidara Therapeutics, Inc.
Cidara Therapeutics Provides Leadership Update

7/1/2021

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that James (Jamie) Levine has resigned from his position as chief financial officer (CFO), effective July 9, 2021, to pursue other opportunities
Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

6/30/2021

Cidara Therapeutics, Inc. today announced that it will present new analyses in four presentations, including an oral presentation on rezafungin, at the 31 st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place virtually from July 9-12, 2021.
Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference

6/14/2021

Cidara Therapeutics, Inc. (Nasdaq: CDTX), today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, and James Levine, Chief Financial Officer, will participate in investor meetings at the Raymond James Human Health Innovation Conference
Cidara to Present at Mycology 2021 Conference

6/2/2021

Cidara Therapeutics, Inc. announced that it will virtually present highlights from pre-clinical through Phase 2 clinical trial data evaluating rezafungin, Cidara’s novel, once-weekly echinocandin, for the treatment and prevention of invasive fungal disease at the Mycology 2021 Conference, which takes place online from June 11-12, 2021.
Cidara Provides Corporate Update and Reports First Quarter 2021 Financial Results

5/13/2021

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended March 31, 2021 and provided an update on its corporate activities and product pipeline.
Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

4/7/2021

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference
J&J Bets Up to $780 Million on Cidara’s Universal Influenza Treatment

4/5/2021

Cidara Therapeutics inked a deal worth up to $780 million with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 for the prevention and treatment of seasonal and pandemic influenza.
Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza

4/5/2021

Collaboration includes exclusive worldwide rights to Cidara’s CD388 and other influenza Antiviral Conjugates (AVCs) for up to $780 million in upfront, milestone payments and R&D funding
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4/1/2021

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 27,000 shares of its common stock to four new employees, pursuant to the Cidara Therapeutics, Inc.
Cidara Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

3/3/2021

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

2/25/2021

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months and full year ended December 31, 2020 and provided an update on its corporate activities and product pipeline.
Cidara Therapeutics Announces New Data for Rezafungin at the 21st ICHS Symposium

2/17/2021

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced data from three posters at the 21 st International Immunocompromised Host Society (ICHS) Symposium on Infections in the Immunocompromised Host, which takes place virtually Feb. 17-19, 2021.
Cidara Therapeutics to Present New Data for Rezafungin and Influenza AVCs at the 21st ICHS Symposium

2/11/2021

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced an oral presentation and four poster presentations at the 21st International Immunocompromised Host Society (ICHS) Symposium on Infections in the Immunocompromised Host, taking place virtually Feb. 17-19, 2021.
BioSpace Movers & Shakers, Jan. 29

1/29/2021

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Cidara Therapeutics Announces Key Additions to its Board of Directors

1/25/2021

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments of internationally-renowned molecular biologist Bonnie Bassler, Ph.D., and seasoned life science executive Carin Canale-Theakston to its board of directors.
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

1/5/2021

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of its Board of Directors granted a stock option to purchase 115,000 shares of its common stock to a new employee, pursuant to the Cidara Therapeutics, Inc.
New and Emerging Drug Classes That Will Outlast the Pandemic

1/5/2021

From synthetic polymer-based anti-infectives to antiviral conjugates and DNA vaccines, the past year has given new and emerging drug classes an opportunity to shine.
BioSpace Movers & Shakers, Dec. 18

12/18/2020

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.